Cucurbitacin B inhibits Th17 cell differentiation via the suppression of the JAK/STAT pathway and alleviates collagen-induced arthritis in mice

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:International Journal of Immunopathology and Pharmacology vol. 39 (Jun 2025)
প্রধান লেখক: Shu-Ping, Kung
অন্যান্য লেখক: Hira, Umbreen, Wang Jou-Hsuan, Chih-Ming, Tsia, Lin Tim Chi-Chen, Yu-Ting, Chen
প্রকাশিত:
Sage Publications Ltd.
বিষয়গুলি:
অনলাইন ব্যবহার করুন:Citation/Abstract
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
বিবরন
সার সংক্ষেপ:Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease with limited treatment options and associated side effects or resistance. This study aims to investigate the therapeutic potential of the natural compound cucurbitacin B (CuB) in RA treatment. Methods: We utilized a collagen-induced arthritis (CIA) mouse model to evaluate the effects of CuB. Arthritis scores, histological damage, and pro-inflammatory cytokine expression (TNF-α, IL-17A) were assessed. In addition, network pharmacology analysis was performed to explore CuB’s molecular mechanisms, focusing on Th17 cell differentiation, IL-17 signaling, and the JAK-STAT pathway. Results: CuB significantly reduced arthritis severity, decreased histological damage, and lowered the expression of pro-inflammatory cytokines in CIA mice. CuB was found to inhibit STAT3 phosphorylation and reduce the proportion of Th17 cells in the spleen, indicating its potential anti-inflammatory effects. Conclusion: These findings suggest that cucurbitacin B may serve as a promising novel therapeutic agent for rheumatoid arthritis by targeting key inflammatory pathways.
আইএসএসএন:0394-6320
2058-7384
ডিওআই:10.1177/03946320251348715
সম্পদ:Health & Medical Collection